HOME >> BIOLOGY >> NEWS
Eastern Europe urged to prepare now for growing threat of HIV resistance

Eastern Europe is warned to prepare for HIV drug resistance, a problem that is now being witnessed in patients in Poland after only five years of HIV treatment being available. Experts at an HIV congress in Warsaw heard today that FUZEON (enfuvirtide, formerly known as T-20), the latest weapon in the fight against HIV drug resistance, is a valuable tool to both patients and payers in the treatment of HIV, particularly when used earlier in pre-treated patients.

Eastern Europe urged to prepare for HIV resistance

John Bowis, OBE, Member of the European Parliament applauds the Ministry of Health in Poland for taking a pro-active lead in the fight against HIV and drug resistance: "The growing problem of HIV resistance is a serious issue which all members of the EU have a responsibility to manage. We must commit to share knowledge, particularly those countries more experienced in tackling the HIV epidemic, in an effort to provide a consistent standard of care and avert a potential healthcare crisis. We need to ensure that all European countries are benefiting from new treatments and are allocating vital resources where they will be of most value."

The increasing prevalence of HIV drug resistance means that many patients can no longer benefit from the first three classes of HIV drugs. Unlike existing anti-HIV drugs, which act inside the cell once it has been infected, FUZEON works on the outside actively blocking the fusion of the virus with cells of the human immune system (CD4 cells). Because of this very different mechanism of action, FUZEON is active against HIV strains that have become resistant to current therapies. FUZEON reduces HIV levels and increases CD4 cell counts even in patients with resistance to the three conventional classes of HIV drugs.

Improving survival in pre-treated patients carrying drug-resistant HIV

Reduction in HIV levels and improvements in CD4 cell counts have been shown to result in improved s
'"/>

Contact: Alexander Watson
Alexander.watson@ketchum.com
44-771-267-5990
Ketchum
27-Oct-2003


Page: 1 2 3

Related biology news :

1. Eastern lowland gorilla population plummets 70 percent since 1994
2. Eastern U.S. benefits from emissions trading by power plants
3. Environment in Eastern Europe benefits from Swedish funding
4. USGS Finds That Mysterious Arkansas Bald Eagle Disease Has Spread To Ducks In Eastern States
5. Clean Air Act Reduces Acid Rain In Eastern U.S.
6. Even Moderate Air Pollution Reaching Eastern Wilderness Decreases Mountain Hikers Lung Function
7. European common frog found to use novel mating strategy
8. Zoonotic diseases - European scientists unite to fight diseases
9. Second call for proposals for the European Young Investigator Award
10. Common call for action on European Research Council (ERC)
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... ARMONK, N.Y. , Aug. 23, 2017  The general public,s help ... the human microbiome—the bacteria that live in and on the human body ... ... bacteria in the human microbiome, starting with the gut. The project's goal ... in disease. Photo credit: IBM ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
Cached News: